Comparing Longeveron (NASDAQ:LGVN) & MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Longeveron (NASDAQ:LGVN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for MoonLake Immunotherapeutics and Longeveron, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	0	4	9	0	2.69
Longeveron	0	0	2	0	3.00

MoonLake Immunotherapeutics presently has a consensus target price of $78.67, suggesting a potential upside of 68.13%. Longeveron has a consensus target price of $8.00, suggesting a potential upside of 292.16%. Given Longeveron’s stronger consensus rating and higher possible upside, analysts clearly believe Longeveron is more favorable than MoonLake Immunotherapeutics.

Earnings and Valuation

This table compares MoonLake Immunotherapeutics and Longeveron’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$36.01 million	($0.75)	-62.39
Longeveron	$1.23 million	10.54	-$21.41 million	($9.61)	-0.21

Longeveron has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 19.1% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares MoonLake Immunotherapeutics and Longeveron’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-7.92%	-7.76%
Longeveron	-2,129.24%	-300.96%	-164.96%

Risk & Volatility

MoonLake Immunotherapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Summary

MoonLake Immunotherapeutics beats Longeveron on 7 of the 13 factors compared between the two stocks.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

About Longeveron

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.